PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers

The spleen tyrosine kinase (SYK) regulates immune cell activation in response to engagement of a variety of receptors, making it an intriguing target for the treatment of inflammatory and autoimmune disorders as well as certain B‐cell malignancies. We have previously reported on the discovery and pr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Pharmacol
Autores principales: Coffey, Greg, Rani, Aradhana, Betz, Andreas, Pak, Yvonne, Haberstock‐Debic, Helena, Pandey, Anjali, Hollenbach, Stanley, Gretler, Daniel D., Mant, Tim, Jurcevic, Stipo, Sinha, Uma
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2016
Materias:
Pharmacodynamics
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5248591/
https://ncbi.nlm.nih.gov/pubmed/27406873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.794
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares